상세 보기
- Ahn, Sung Ho;
- Lee, Hyun Jung;
- Pyun, Do Hyeon;
- Kim, Tae Jin;
- Abd El-Aty, A.M.;
- ... Song, Jin-Ho;
- ... Shin, Yong Kyoo;
- ... Jeong, Ji Hoon;
- ... Jung, Tae Woo;
- 외 1명
WEB OF SCIENCE
3SCOPUS
3초록
Recently, there is a rapid increase in the incidence of obesity, a condition for which there are no effective therapeutic agents. Capmatinib (CAP), a novel mesenchymal-to-epithelial transition inhibitor, is reported to attenuate pro-inflammatory mediators and oxidative stress. In this study, the effects of CAP on lipogenesis in the adipocytes were examined. Treatment with CAP dose-dependently suppressed lipid accumulation in, and differentiation of, and increased lipolysis in, 3T3-L1 adipocytes. Additionally, CAP treatment augmented adenosine monophosphate-activated protein kinase (AMPK) phosphorylation and FNDC5 expression in the adipocytes. Transfection with si-AMPK or si-FNDC5 mitigated the CAP-induced suppression of lipogenesis and enhanced lipolysis. Furthermore, transfection with si-FNDC5 mitigated the CAP-induced phosphorylation of AMPK. These results suggest that the anti-obesity effect of CAP is mediated through the irisin/AMPK pathway and that CAP is a novel therapeutic agent for obesity. © 2021 Elsevier Inc.
키워드
- 제목
- Capmatinib attenuates lipogenesis in 3T3-L1 adipocytes through an adenosine monophosphate-activated protein kinase-dependent pathway
- 저자
- Ahn, Sung Ho; Lee, Hyun Jung; Pyun, Do Hyeon; Kim, Tae Jin; Abd El-Aty, A.M.; Song, Jin-Ho; Shin, Yong Kyoo; Jeong, Ji Hoon; Park, Eon Sub; Jung, Tae Woo
- 발행일
- 2021-05
- 유형
- Article
- 권
- 553
- 페이지
- 30 ~ 36